To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
GeneQuine develops gene therapy-based drugs for the treatment of osteoarthritis. The goal is the development of a gene therapy drug for osteoarthritis in humans. However, GeneQuine focuses initially on gaining market authorization for its drug candidates for horses and dogs, because obtaining regulatory approval for veterinary drugs is significantly less costly and markedly faster compared with human medicines.
Revolutionizing the Treatment of Osteoarthritis to Improve Patients' Mobility and Quality of Life.
GQ-201 is a gene therapy product candidate for the treatment of osteoarthritis in horses. The product candidates GQ-202 and GQ-203 are the respective analogues for osteoarthritis in dogs and humans. In December 2017, GQ-203 was acquired by Flexion Therapeutics, Inc. and is now called FX201. GeneQuine is also developing the gene therapy product candidates GQ-301, GQ-302 and GQ-303 for osteoarthritis in horses, dogs and humans, respectively. Compared to the 200 series, these product candidates express a protein with a different pharmacological profile and mechanism of action.